Cited by 106Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatmentsHereditary Neurological Disorders

The DOI matches its Crossref record; 151 of the 154 references it cites were found in a registry or an index.

Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis

Open access

Nowicka, Natalia, Juranek, Jakub, Juranek, Judyta K., Wojtkiewicz, Joanna·2019·International Journal of Molecular Sciences

DOI 10.3390/ijms20112616PMC PMC6600314

Open this paper in CoChat — free account Open PDF

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease characterized by a permanent degeneration of both upper and lower motor neurons. Many different genes and pathophysiological processes contribute to this disease, however its exact cause remains unclear. Therefore, it is necessary to understand this heterogeneity to find effective treatments. In this review, we focus on selected environmental and genetic risk factors predisposing to ALS and highlight emerging treatments in ALS therapy. Of numerous defective genes associated with ALS, we focus on four principal genes that have been identified as definite causes of ALS: the SOD1 gene, C9orf72, TDP-43, as well as the recently identified TBK1. We also provide up-to-date information on selected environmental factors that have historically been considered as key players in ALS development and pathogenesis. In parallel to our survey of known risk factors, we also discuss emerging ALS stem cell therapies and experimental medicines currently undergoing phase II and III clinical trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/ijms20112616

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Schematic depiction of risk factors in ALS. ALS risk factors can be divided into two main categories: genetic and environmental. Well-documented genetic factors include mutations in superoxide dismutase 1 (SOD1 gene), mutation in TAR DNA binding protein (TARDBP), a hexanucleotide repeat expansion (GGGGCC) in the first intron of the C9orf72 gene, and mutations in TANK-binding kinase 1 (TBK1). The researched environmental risk factors are BMI and nutritional state and exposure to heavy metals, pesticides, and electromagnetic fields.CC BY · PubMed Central

Figure 2 Overview of main approaches to ALS treatment. The therapies studied can be divided into seven general groups, mainly based on pathophysiological models of the disease. The groups include anti-apoptotic, anti-inflammatory, anti-excitotoxicitory, anti-oxidant, anti-aggregation, neurotrophic growth factor, and neuroprotective approaches, which all can be classified as pharmacological interventions. Additionally, a separate non-pharmacological group of stem cell therapies is discussed.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Superoxide Dismutase
McCord, J. M., & Fridovich, I. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63504-5 · Cited by 12,952
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Polazzi, E., Mengoni, I., Caprini, M., Peña‐Altamira, E., Kurtys, E., & Monti, B. (2012) · Neurosignals · doi:10.1159/000337115 · Cited by 9,023
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 1×
“In FTD, it has been detected in 25% of all patients with familial ALS, underlining the importance of the hypothesis that classical ALS and FTD represent the extremes of a single mutation spectrum [41].”
Background
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis
Kwiatkowski, T. J., Bosco, D. A., LeClerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J. M., Kasarskis, E. J., Munsat, T. L., et al. (2009) · Science · doi:10.1126/science.1166066 · Cited by 2,624
Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression
Zelko, I. N., Mariani, T. J., & Folz, R. J. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00905-x · Cited by 2,212
Toxic Metals and Oxidative Stress Part I: Mechanisms Involved in Me-tal induced Oxidative Damage
Nuran Ercal, B. S. P., Hande Gurer-Orhan, B. S. P., & Nukhet Aykin-Burns, B. S. P. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013394831 · Cited by 1,944
Amyotrophic Lateral Sclerosis
Rowland, L. P., & Shneider, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442207 · Cited by 1,913
Mutations of optineurin in amyotrophic lateral sclerosis
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H., et al. (2010) · Nature · doi:10.1038/nature08971 · Cited by 1,265
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study
Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia
Deng, H.-X., Chen, W., Hong, S.-T., Boycott, K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., et al. (2011) · Nature · doi:10.1038/nature10353 · Cited by 1,174
Amyotrophic lateral sclerosis
Wijesekera, L. C., & Leigh, P. N. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-3 · Cited by 1,130
Molecular biology of amyotrophic lateral sclerosis: insights from genetics
Pasinelli, P., & Brown, R. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1971 · Cited by 1,107
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
Rosen, D. (1993) · Nature · doi:10.1038/364362c0 · Cited by 922
The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria
Thurston, T. L. M., Ryzhakov, G., Bloor, S., von Muhlinen, N., & Randow, F. (2009) · Nature Immunology · doi:10.1038/ni.1800 · Cited by 901
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia
Freischmidt, A., Wieland, T., Richter, B., Ruf, W., Schaeffer, V., Müller, K., Marroquin, N., Nordin, F., Hübers, A., Weydt, P., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4000 · Cited by 786
A comprehensive review of amyotrophic lateral sclerosis
Zarei, S., Carr, K., Reiley, L. E., Diaz, K., Guerra, O., Altamirano, P., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. R. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.169561 · Cited by 775
Incidence of amyotrophic lateral sclerosis in Europe
Logroscino, G., Traynor, B. J., Hardiman, O., Chio, A., Mitchell, D., Swingler, R. J., Millul, A., Benn, E., Beghi, E., & EURALS, F. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.183525 · Cited by 772
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615
Amyotrophic lateral sclerosis
Mitchell, J. D., & Borasio, G. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60944-1 · Cited by 606
Misfolded CuZnSOD and amyotrophic lateral sclerosis
Valentine, J. S., & Hart, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730423100 · Cited by 546
Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis
Zou, Z.-Y., Zhou, Z.-R., Che, C.-H., Liu, C.-Y., He, R.-L., & Huang, H.-P. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315018 · Cited by 540
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease
Buratti, E. (2007) · Frontiers in bioscience · doi:10.2741/2727 · Cited by 493
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Jaiswal, M. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21528 · Cited by 474
Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis
Rutherford, N. J., Zhang, Y., Baker, M. C., Gass, J. M., Finch, N. A., Xu, Y., Stewart, H. G., Kelley, B. J., Kuntz, K., Crook, R., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000193 · Cited by 465
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
Focal transplantation–based astrocyte replacement is neuroprotective in a model of motor neuron disease
Lepore, A. C., Rauck, B., Dejea, C., Pardo, A. C., Rao, M. S., Rothstein, J. D., & Maragakis, N. J. (2008) · Nature Neuroscience · doi:10.1038/nn.2210 · Cited by 441
T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS
Chiu, I. M., Chen, A., Zheng, Y., Kosaras, B., Tsiftsoglou, S. A., Vartanian, T. K., Brown, R. H., & Carroll, M. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804610105 · Cited by 380
SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model
Harraz, M. M., Marden, J. J., Zhou, W., Zhang, Y., Williams, A. J., Sharov, V. S., Nelson, K., Luo, M., Paulson, H. L., Schöneich, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34060 · Cited by 375
Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene
Andersen, P. M. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0008-9 · Cited by 368
Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis
Byrne, S., Walsh, C., Lynch, C., Bede, P., Elamin, M., Kenna, K. P., McLaughlin, R. L., & Hardiman, O. M. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.224501 · Cited by 364
Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation
Afroz, T., Hock, E., Erñst, P., Foglieni, C., Jambeau, M., Gilhespy, L. A. B., Laferrière, F., Maniecka, Z., Plückthun, A., Mittl, P. R. E., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00062-0 · Cited by 358
Microglia in ALS: The Good, The Bad, and The Resting
Henkel, J. S., Beers, D. R., Zhao, W., & Appel, S. H. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9171-5 · Cited by 353
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72
Cooper‐Knock, J., Hewitt, C., Highley, J. R., Brockington, A., Milano, A., Man, S., Martindale, J. E., Hartley, J. A., Walsh, T., Gelsthorpe, C., et al. (2012) · Brain · doi:10.1093/brain/awr365 · Cited by 342
Is SOD1 loss of function involved in amyotrophic lateral sclerosis?
Saccon, R. A., Bunton-Stasyshyn, R. K. A., Fisher, E., & Fratta, P. (2013) · Brain · doi:10.1093/brain/awt097 · Cited by 339
Amyotrophic Lateral Sclerosis: An Update for 2018
Oskarsson, B., Gendron, T. F., & Staff, N. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.007 · Cited by 338
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis
D’Amico, E., Factor-Litvak, P. R., Santella, R. M., & Mitsumoto, H. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.029 · Cited by 328
Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease
Pottier, C., Bieniek, K. F., Finch, N., van de Vorst, M., Baker, M., Perkersen, R., Brown, P., Ravenscroft, T., van Blitterswijk, M., Nicholson, A. M., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1436-x · Cited by 312
Extracellular Vesicles from Neural Stem Cells Transfer IFN-γ via Ifngr1 to Activate Stat1 Signaling in Target Cells
Cossetti, C., Iraci, N., Mercer, T. R., Leonardi, T., Alpi, E., Drago, D., Alfaro‐Cervelló, C., Saini, H. K., Davis, M. P. A., Schaeffer, J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.020 · Cited by 305
Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death
Kasarskis, E. J., Berryman, S., Vanderleest, J. G., Schneider, A., & McClain, C. J. (1996) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/63.1.130 · Cited by 293
Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis
Paganoni, S., Deng, J., Jaffa, M., Cudkowicz, M., & Wills, A.-M. A. (2011) · Muscle & Nerve · doi:10.1002/mus.22114 · Cited by 293
Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study
Laaksovirta, H., Peuralinna, T., Schymick, J. C., Scholz, S. W., Lai, S.-L., Myllykangas, L., Sulkava, R. O., Jansson, L., Hernandez, D. G., Gibbs, J. R., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70184-8 · Cited by 260
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30054-1 · Cited by 259
Potential occupational risks for neurodegenerative diseases
Park, R. M., Schulte, P. A., Bowman, J. D., Walker, J. T., Bondy, S. C., Yost, M. G., Touchstone, J. A., & Dosemeci, M. (2005) · American Journal of Industrial Medicine · doi:10.1002/ajim.20178 · Cited by 256
Extremely low frequency electromagnetic fields as effectors of cellular responses in vitro: Possible immune cell activation
Simkó, M., & Mattsson, M. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20198 · Cited by 256
Crystal Structure and Mechanism of Activation of TANK-Binding Kinase 1
Larabi, A., Devos, J. M., Ng, S., Nanao, M., Round, A. R., Maniatis, T., & Panne, D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.034 · Cited by 253
Occupational Exposures and Amyotrophic Lateral Sclerosis. A Population-based Case-Control Study
McGuire, V. M., Longstreth, W. T., Jr., Nelson, L. M., Koepsell, T. D., Checkoway, H., Morgan, M. S., & van Belle, G. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009070 · Cited by 235
Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis
Wang, M.-D., Little, J., Gomes, J., Cashman, N. R., & Krewski, D. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2016.06.015 · Cited by 233
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial
Cudkowicz, M., van den Berg, L. H., Shefner, J. M., Mitsumoto, H., Mora, J. S., Ludolph, A. C., Hardiman, O. M., Bozik, M. E., Ingersoll, E. W., Archibald, D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70221-7 · Cited by 232
Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era
Paez-Colasante, X., Figueroa‐Romero, C., Sakowski, S. A., Goutman, S. A., & Feldman, E. L. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.57 · Cited by 227
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
Elia, A. E., Lalli, S., Monsurrò, M. R., Sagnelli, A., Taiello, A. C., Reggiori, B., Bella, V. L., Tedeschi, G., & Albanese, A. (2015) · European Journal of Neurology · doi:10.1111/ene.12664 · Cited by 225
TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation
Ou, Y.-H., Torres, M. J., Ram, R. R., Formstecher, É., Roland, C. L., Cheng, T., Brekken, R. A., Wurz, R. P., Tasker, A. S., Polverino, T., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.01.019 · Cited by 224
Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1
Tu, D., Zhu, Z., Zhou, A. Y., Yun, C., Lee, K., Toms, A. V., Li, Y., Dunn, G. P., Chan, E. M., Thai, T. C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.033 · Cited by 222
Evolution of CuZn superoxide dismutase and the Greek Key β‐barrel structural motif
Getzoff, E. D., Tainer, J. A., Stempien, M. M., Bell, G. I., & Hallewell, R. A. (1989) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340050408 · Cited by 209
An Evidence-Based Medicine Approach to the Evaluation of the Role of Exogenous Risk Factors in Sporadic Amyotrophic Lateral Sclerosis
Armon, C. (2003) · Neuroepidemiology · doi:10.1159/000070562 · Cited by 209
An Analysis of Extended Survival in Patients With Amyotrophic Lateral Sclerosis Treated With Riluzole
Rivière, M., Meininger, V., Zeisser, P., & Munsat, T. L. (1998) · Archives of Neurology · doi:10.1001/archneur.55.4.526 · Cited by 198
Pathogenesis of amyotrophic lateral sclerosis
Morgan, S. L., & Orrell, R. W. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw026 · Cited by 189
A CASE-CONTROL STUDY OF AMYOTROPHIC LATERAL SCLEROSIS1
DEAPEN, D. M., & HENDERSON, B. E. (1986) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114308 · Cited by 187
Premorbid body mass index and risk of amyotrophic lateral sclerosis
O’Reilly, É. J., Wang, H., Weisskopf, M. G., Fitzgerald, K. C., Falcone, G. J., McCullough, M. L., Thun, M. J., Park, Y., Kolonel, L. N., & Ascherio, A. (2012) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2012.735240 · Cited by 179
Polyubiquitin Binding to Optineurin Is Required for Optimal Activation of TANK-binding Kinase 1 and Production of Interferon β
Gleason, C. E., Ordureau, A., Gourlay, R., Arthur, J. S. C., & Cohen, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.267567 · Cited by 177
Dissociation of Human Copper-Zinc Superoxide Dismutase Dimers Using Chaotrope and Reductant
Doucette, P. A., Whitson, L. J., Cao, X., Schirf, V. R., Demeler, B., Valentine, J. S., Hansen, J. C., & Hart, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409744200 · Cited by 170
SOD1 in Amyotrophic Lateral Sclerosis: “Ambivalent” Behavior Connected to the Disease
Pansarasa, O., Bordoni, M., Diamanti, L., Sproviero, D., Gagliardi, S., & Cereda, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051345 · Cited by 170
Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: A systematic review
Sutedja, N. A., Veldink, J. H., Fischer, K., Kromhout, H., Heederik, D. J. J., Huisman, M. H. B., Wokke, J. H. J., & van den Berg, L. H. (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802455416 · Cited by 161
TBK1 Mediates Crosstalk Between the Innate Immune Response and Autophagy
Weidberg, H., & Elazar, Z. (2011) · Science Signaling · doi:10.1126/scisignal.2002355 · Cited by 157
Neurodegenerative Diseases in Welders and Other Workers Exposed to High Levels of Magnetic Fields
Håkansson, N., Gustavsson, P., Johansen, C., & Floderus, B. (2003) · Epidemiology · doi:10.1097/01.ede.0000078446.76859.c9 · Cited by 155
Potential Environmental Factors in Amyotrophic Lateral Sclerosis
Oskarsson, B., Horton, D. K., & Mitsumoto, H. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.009 · Cited by 153
An outcome study of riluzole in amyotrophic lateral sclerosis
Traynor, B. J., Alexander, M. D., Corr, B., Frost, E., & Hardiman, O. M. (2003) · Journal of Neurology · doi:10.1007/s00415-003-1026-z · Cited by 152
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases
Southwell, A. L., Skotte, N. H., Bennett, C. F., & Hayden, M. R. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.09.001 · Cited by 140
Mitochondrial dysfunction in amyotrophic lateral sclerosis – a valid pharmacological target?
Muyderman, H., & Chen, T. H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12476 · Cited by 138
Delayed Disease Onset and Extended Survival in the SOD1G93ARat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex
Thomsen, G. M., Gowing, G., Latter, J., Chen, M., Vit, J., Staggenborg, K., Avalos, P., Alkaslasi, M. R., Ferraiuolo, L., Likhite, S. B., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2037-14.2014 · Cited by 137
Riluzole, disease stage and survival in ALS
Dharmadasa, T., & Kiernan, M. C. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30091-7 · Cited by 135
Advances in motor neurone disease
Bäumer, D., Talbot, K., & Turner, M. R. (2014) · Journal of the Royal Society of Medicine · doi:10.1177/0141076813511451 · Cited by 134
Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
The link of organophosphorus pesticides with neurodegenerative and neurodevelopmental diseases based on evidence and mechanisms
Mostafalou, S., & Abdollahi, M. R. (2018) · Toxicology · doi:10.1016/j.tox.2018.07.014 · Cited by 130
The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis
Tanaka, H., Shimazawa, M., Kimura, M., Takata, M., Tsuruma, K., Yamada, M., Takahashi, H., Hozumi, I., Niwa, J., Iguchi, Y., et al. (2012) · Scientific Reports · doi:10.1038/srep00573 · Cited by 129
Amyotrophic lateral sclerosis and environmental factors
Bozzoni, V. (2016) · Functional Neurology · doi:10.11138/fneur/2016.31.1.007 · Cited by 127
Association Between Blood Lead and the Risk of Amyotrophic Lateral Sclerosis
Fang, F., Kwee, L. C., Allen, K. D., Umbach, D. M., Ye, W., Watson, M., Keller, J., Oddone, E. Z., Sandler, D. P., Schmidt, S., et al. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq063 · Cited by 121
Structural insights into the ubiquitin recognition by OPTN (optineurin) and its regulation by TBK1-mediated phosphorylation
Li, F., Xu, D., Wang, Y., Zhou, Z., Liu, J., Hu, S., Gong, Y., Yuan, J., & Pan, L. (2018) · Autophagy · doi:10.1080/15548627.2017.1391970 · Cited by 120
Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS
Lepore, A. C., O'Donnell, J., Kim, A. S., Williams, T. L., Tuteja, A., Rao, M. S., Kelley, L. L., Campanelli, J. T., & Maragakis, N. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025968 · Cited by 118
Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis
Lindauer, E., Dupuis, L., Müller, H., Heiko Neumann, B., Ludolph, A. C., & Kassubek, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067783 · Cited by 114
Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options
Körner, S., Hendricks, M., Kollewe, K., Zapf, A., Dengler, R., Silani, V., & Petri, S. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-84 · Cited by 112
Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
Dorst, J., Ludolph, A. C., & Huebers, A. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617734734 · Cited by 111
Aberrantly Increased Hydrophobicity Shared by Mutants of Cu,Zn-Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis
Tiwari, A., Xu, Z., & Hayward, L. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504039200 · Cited by 108
Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis
Simpson, E. P., Yen, A. A., & Appel, S. H. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200311000-00008 · Cited by 107
Edaravone for the treatment of amyotrophic lateral sclerosis
Yoshino, H. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1581610 · Cited by 104
Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies
Cascella, R., Capitini, C., Fani, G., Dobson, C. M., Cecchi, C., & Chiti, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.737726 · Cited by 101
Exposure to Electromagnetic Fields and Risk of Central Nervous System Disease in Utility Workers
Johansen, C. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00009 · Cited by 100
Non‐neuronal Cells in ALS: Role of Glial, Immune cells and Blood‐CNS Barriers
Puentes, F., Malaspina, A., van Noort, J. M., & Amor, S. (2016) · Brain Pathology · doi:10.1111/bpa.12352 · Cited by 100
Randomized phase 2 trial of NP001, a novel immune regulator
Miller, R. G., Block, G. A., Katz, J., Barohn, R. J., Gopalakrishnan, V., Cudkowicz, M., Zhang, J. R., McGrath, M. S., Ludington, E. A., Appel, S. H., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000100 · Cited by 97
Association of Mutations in TBK1 With Sporadic and Familial Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Freischmidt, A., Müller, K., Ludolph, A. C., Weishaupt, J. H., & Andersen, P. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3712 · Cited by 95
Paraoxonase gene polymorphisms and sporadic ALS
Słowik, A., Tomik, B., Wołkow, P. P., Partyka, D., Turaj, W., Malecki, M. T., Pera, J., Dziedzic, T., Szczudlik, A., & Figlewicz, D. A. (2006) · Neurology · doi:10.1212/01.wnl.0000219565.32247.11 · Cited by 93
Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy
Martier, R., Liefhebber, J. M. P., García‐Osta, A., Miniarikova, J., Cuadrado‐Tejedor, M., Espelosin, M., Ursúa, S., Petry, H., van Deventer, S. J. H., Evers, M. M., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.001 · Cited by 91
7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis
Korkmaz, O. T., Aytan, N., Carreras, I., Choi, J., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.02.058 · Cited by 90
Edaravone and its clinical development for amyotrophic lateral sclerosis
Takei, K., Watanabe, K., Yuki, S., Akimoto, M., Sakata, T., & Palumbo, J. (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2017.1353101 · Cited by 90
Edaravone: a new hope for deadly amyotrophic lateral sclerosis
Bhandari, R., Kuhad, A., & Kuhad, A. (2018) · Drugs of today · doi:10.1358/dot.2018.54.6.2828189 · Cited by 89
Current Challenges for the Advancement of Neural Stem Cell Biology and Transplantation Research
Reekmans, K., Praet, J., Daans, J., Reumers, V., Pauwels, P., der Linden, A. V., Berneman, Z. N., & Ponsaerts, P. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9266-2 · Cited by 87
Amyotrophic lateral sclerosis: toxins and environment
Mitchell, J. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820050515061 · Cited by 87
Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS
Geevasinga, N., Menon, P., Ng, K., van den Bos, M. A. J., Byth, K., Kiernan, M. C., & Vucic, S. (2016) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2016.1188961 · Cited by 83
Paraoxonase gene mutations in amyotrophic lateral sclerosis
Ticozzi, N., LeClerc, A. L., Keagle, P. J., Glass, J. D., Wills, A.-M. A., van Blitterswijk, M., Bosco, D. A., Rodríguez‐Leyva, I., Gellera, C., Ratti, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21993 · Cited by 80
Exposure to Environmental Toxicants and Pathogenesis of Amyotrophic Lateral Sclerosis: State of the Art and Research Perspectives
Trojsi, F., Monsurrò, M. R., & Tedeschi, G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815286 · Cited by 78
Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genes.
Kamel, F., Umbach, D. M., Lehman, T. A., Park, L. P., Munsat, T. L., Shefner, J. M., Sandler, D. P., Hu, H., & Taylor, J. A. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6109 · Cited by 77
Caloric Restriction Shortens Lifespan through an Increase in Lipid Peroxidation, Inflammation and Apoptosis in the G93A Mouse, an Animal Model of ALS
Patel, B. P., Safdar, A., Raha, S., Tarnopolsky, M. A., & Hamadeh, M. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009386 · Cited by 76
Oropharyngeal dysphagia in amyotrophic lateral sclerosis alters quality of life
Paris, G., Martinaud, O., Petit, A., Cuvelier, A., Hannequin, D., Roppenneck, P., & Vérin, É. (2012) · Journal of Oral Rehabilitation · doi:10.1111/joor.12019 · Cited by 76
Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis
Sasaki, S., Horie, Y., & Iwata, M. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0299-1 · Cited by 75
Association between Extremely Low-Frequency Electromagnetic Fields Occupations and Amyotrophic Lateral Sclerosis: A Meta-Analysis
Zhou, H., Chen, G., Chen, C., Yu, Y., & Xu, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048354 · Cited by 75
A Meta-Analysis of Observational Studies of the Association Between Chronic Occupational Exposure to Lead and Amyotrophic Lateral Sclerosis
Wang, M., Gomes, J., Cashman, N. R., Little, J., & Krewski, D. R. (2014) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000000323 · Cited by 74
Genetic susceptibility to environmental toxicants in ALS
Morahan, J. M., Yu, B., Trent, R. J., & Pamphlett, R. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30543 · Cited by 73
Stem Cell Technology for the Study and Treatment of Motor Neuron Diseases
Lunn, J. S., Sakowski, S. A., Federici, T., Glass, J. D., Boulis, N. M., & Feldman, E. L. (2011) · Regenerative Medicine · doi:10.2217/rme.11.6 · Cited by 72
Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases
Hübers, A., Marroquin, N., Schmoll, B., Vielhaber, S., Just, M., Mayer, B., Högel, J., Dorst, J., Mertens, T., Just, W., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.034 · Cited by 69
MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for familial ALS
Shvil, N., Banerjee, V., Zoltsman, G., Shani, T., Kahn, J., Abu‐Hamad, S., Papo, N., Engel, S., Bernhagen, J., & Israelson, A. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0130-4 · Cited by 69
Aggregated SOD1 causes selective death of cultured human motor neurons
Benkler, C., O’Neil, A., Slepian, S., Qian, F., Weinreb, P. H., & Rubin, L. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-34759-z · Cited by 68
Neural stem cells: therapeutic potential for neurodegenerative diseases
Gincberg, G., Arien‐Zakay, H., Lazarovici, P., & Lelkes, P. I. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds024 · Cited by 66
EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis
Rosenblum, L. T., & Trotti, D. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-55769-4_6 · Cited by 66
Oxidative stress: the lowest common denominator of multiple diseases
Matschke, V., Theiß, C., & Matschke, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.244780 · Cited by 65
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis
Vucic, S., Krishnan, A. V., & Kiernan, M. C. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.112078 · Cited by 63
Current and emerging treatments for amyotrophic lateral sclerosis
Zoccolella (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s7788 · Cited by 62
Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients
Reich‐Slotky, R., Andrews, J. A., Cheng, B., Buchsbaum, R., Levy, D., Kaufmann, P., & Thompson, J. L. P. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.770028 · Cited by 62
Association between occupational exposure to power frequency electromagnetic fields and amyotrophic lateral sclerosis: A review
Li, C., & Sung, F. (2003) · American Journal of Industrial Medicine · doi:10.1002/ajim.10148 · Cited by 59
Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin
Amlie‐Wolf, A., Ryvkin, P., Tong, R., Dragomir, I. C., Suh, E. R., Xu, Y., Deerlin, V. M. V., Gregory, B. D., Kwong, L. K., Trojanowski, J. Q., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141836 · Cited by 57
Prospective Study of Occupation and Amyotrophic Lateral Sclerosis Mortality
Weisskopf, M. G., McCullough, M. L., Morozova, N., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi343 · Cited by 55
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
Bozik, M. E., Mitsumoto, H., Brooks, B. R., Rudnicki, S. A., Moore, D. H., Zhang, B., Ludolph, A., Cudkowicz, M., van den Berg, L. H., Mather, J. L., et al. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.943672 · Cited by 53
Impaired Autophagy and Defective Mitochondrial Function: Converging Paths on the Road to Motor Neuron Degeneration
Edens, B. M., Miller, N., & Ma, Y. C. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00044 · Cited by 52
FUS-regulated RNA metabolism and DNA damage repair
Zhou, Y., Liu, S., Öztürk, A., & Hicks, G. G. (2014) · Rare Diseases · doi:10.4161/rdis.29515 · Cited by 50
Effect of Acute Extremely Low Frequency Electromagnetic Field Exposure on the Antioxidant Status and Lipid Levels in Rat Brain
Martínez-Sámano, J., Torres-Durán, P. V., Juárez-Oropeza, M. A., & Verdugo‐Díaz, L. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.04.003 · Cited by 49
Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects
Thomsen, G. M., Alkaslasi, M. R., Vit, J., Lawless, G., Godoy, M. I., Gowing, G., Shelest, O., & Svendsen, C. N. (2017) · Gene Therapy · doi:10.1038/gt.2017.9 · Cited by 46
“ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities
Harrison, D. S., Mehta, P., van Es, M. A., Stommel, E. W., Drory, V. E., Nefussy, B., van den Berg, L. H., Crayle, J. I., Bedlack, R., & the Pooled Resource Open-Access ALS Clinical Trials Consortium (2018) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2018.1457059 · Cited by 46
Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
Lauria, G., Bella, E. D., Antonini, G., Borghero, G., Capasso, M., Caponnetto, C., Chiò, A., Corbo, M., Eleopra, R., Fazio, R., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308996 · Cited by 41
Riluzole therapy for motor neurone disease: An early Australian experience (1996–2002)
Zoing, M. C., Burke, D. J., Pamphlett, R., & Kiernan, M. C. (2006) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.04.011 · Cited by 40
Stem cells therapy for ALS
Mazzini, L., Vescovi, A. L., Cantello, R. M., Gelati, M., & Vercelli, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1116516 · Cited by 39
GPNMB ameliorates mutant TDP‐43‐induced motor neuron cell death
Nagahara, Y., Shimazawa, M., Ohuchi, K., Itô, J., Takahashi, H., Tsuruma, K., Kakita, A., & Hara, H. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23999 · Cited by 39
Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis
Cui, R., Tuo, M., Li, P., & Zhou, C. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3246-0 · Cited by 38
Genetics of Amyotrophic Lateral Sclerosis
Siddique, N., & Siddique, T. (2008) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2008.05.001 · Cited by 35
Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives
Khairoalsindi, O. A., & Abuzinadah, A. R. (2018) · Neurology Research International · doi:10.1155/2018/6534150 · Cited by 35
The relevance of contact-independent cell-to-cell transfer of TDP-43 and SOD1 in amyotrophic lateral sclerosis
Hanspal, M. A., Dobson, C. M., Yerbury, J. J., & Kumita, J. R. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.007 · Cited by 30
Oxidative Stress as “Mother” of Many Human Diseases at Strong Clinical Impact
Cacciapuoti, F. (2016) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000020 · Cited by 28
A Meta-Analysis on the Relationship of the PON Genes and Alzheimer Disease
Nie, Y., Luo, D., Yang, M., Wang, Y., Li, X., Gao, L., Liu, Y., & Liu, H. (2017) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988717731825 · Cited by 27
The molecular pathogenesis of superoxide dismutase 1-linked ALS is promoted by low oxygen tension
Keskin, I., Forsgren, E., Lehmann, M., Andersen, P. M., Brännström, T., Lange, D. J., Synofzik, M., Nordström, U., Zetterström, P., Marklund, S. L., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01986-1 · Cited by 27
Progress towards therapy in motor neuron disease
Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.186 · Cited by 25
Capturing VCP: Another Molecular Piece in the ALS Jigsaw Puzzle
Shaw, C. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.040 · Cited by 24
Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration
Vieira, F. G., LaDow, E., Moreno, A. J., Kidd, J. D., Levine, B. A., Thompson, K., Gill, A., Finkbeiner, S. M., & Perrin, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091608 · Cited by 24
Human glial progenitor engraftment and gene expression is independent of the ALS environment
Haidet-Phillips, A. M., Doreswamy, A., Gross, S. K., Tang, X., Campanelli, J. T., & Maragakis, N. J. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.12.011 · Cited by 24
Early post-marketing experience with edaravone in an unselected group of patients with ALS
Abraham, A., Nefussy, B., Fainmesser, Y., Ebrahimi, Y., Karni, A., & Drory, V. E. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1572191 · Cited by 24
Amyotrophic Lateral Sclerosis - Cell Based Therapy and Novel Therapeutic Development
Kim, C., Lee, H. C., & Sung, J. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.3.207 · Cited by 20
Regulation of FMO and PON Detoxication Systems in ALS Human Tissues
Gagliardi, S., Abel, K. J., Bianchi, M., Milani, P., Bernuzzi, S., Corato, M. D., Ceroni, M., Cashman, J. R., & Cereda, C. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9356-1 · Cited by 19
The C9orf72 hexanucleotide repeat expansion in FTD and ALS
Bigio, E. H. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.58 · Cited by 15
Advances in the Research of Astrocyte Function in Neural Regeneration
Srikanth, M., Yao, L., & Asmatulu, R. (2018) · Springer eBooks · doi:10.1007/978-3-030-02104-7_1 · Cited by 2

Research works printed but not linked: 1

Parry, 2016, Ursodeoxycholic Acid May Slow the Progression of Amyotrophic Lateral Sclerosis, Ann. Neurodegener. Dis., 1, 1013

Sorted by citations

Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System
Malik, A. R., & Willnow, T. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225671 · Cited by 170
The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders
Tripathi, M. K., Kartawy, M., & Amal, H. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101567 · Cited by 163
Role of Alcohol Drinking in Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis
Peng, B., Yang, Q., B Joshi, R., Liu, Y., Akbar, M., Song, B.-J., Zhou, S., & Wang, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072316 · Cited by 156
Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
Cho, H., & Shukla, S. (2020) · Pharmaceuticals · doi:10.3390/ph14010029 · Cited by 124
Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)
Abati, E., Bresolin, N., Comi, G. P., & Corti, S. P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1738390 · Cited by 107

See all 106

Authors: Nowicka, N., Juranek, J., Juranek, J. K., & Wojtkiewicz, J.
Affiliations: University of Warmia and Mazury in Olsztyn (PL)
Institute of Psychology (PL)
Corresponding author: Nowicka, Natalia
Wojtkiewicz, Joanna
ORCID: Nowicka, Natalia
Juranek, Jakub
Juranek, Judyta K.
Wojtkiewicz, Joanna
Venue: International Journal of Molecular Sciences
Publisher: MDPI AG
Published: 2019-05-28
Volume: 20
Issue: 11
Pages: 2616
ISSN: 1422-0067 (ISSN-L)
DOI: 10.3390/ijms20112616
PMC: PMC6600314
OpenAlex: W2947955929
Cited by: 106
References: 154
Citations by year: 2026: 11 · 2025: 10 · 2024: 11 · 2023: 22 · 2022: 17 · 2021: 12 · 2020: 20 · 2019: 3
FWCI: 1.74
Type: journal article
Language: en
Open access: gold
dx.doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: International Journal of Molecular Sciences (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: Narodowym Centrum Nauki (OPUS/2017/25/B/NZ4/00435)
Topics: Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords: amyotrophic lateral sclerosis, risk factors, genetic risk factors, environmental risk factors, SOD1, C9orf72, TDP-43, TBK1, motor neuron degeneration, stem cell therapy, experimental treatment, clinical trials
MeSH terms: Superoxide Dismutase-1, C9orf72 Protein, Amyotrophic Lateral Sclerosis, Animals, DNA-Binding Proteins, Humans, Genetic Therapy, Genetic Predisposition to Disease, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks